---
title: "Obefazimod (ABX464) in Ulcerative colitis: Janus kinase inhibitors"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Janus kinase inhibitors. Topics: ACG 2025 guideline: recommendations for induction and maintenance, Pivotal trial results for tofacitinib and upadacitinib: ACG 2025 evidence summary, U.S. positioning after TNF antagonist failure: ACG 2025, Restricted first-line use: AGA 2024 guideline, and 5 further topics. 9 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/janus-kinase-inhibitors"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Janus kinase inhibitors

<a id="heading-2.2.2.1.8"></a>

## 2.2.2.1.8 Janus Kinase Inhibitors

<a id="topic-2.2.2.1.8-1"></a>

### ACG 2025 guideline: recommendations for induction and maintenance

> “In patients with moderately to severely active UC, we recommend the Janus kinase (JAK) inhibitor tofacitinib for induction of remission (Strong recommendation, moderate quality of evidence).”
> “In patients with moderately to severely active UC, we recommend the JAK inhibitor upadacitinib for induction of remission (Strong recommendation, high quality of evidence).”
> “We recommend continuing tofacitinib or upadacitinib as compared with no treatment for maintenance of remission in patients with prior moderately to severely active UC now in remission after induction with tofacitinib or upadacitinib (Strong recommendation, moderate quality of evidence).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.8-2"></a>

### Pivotal trial results for tofacitinib and upadacitinib: ACG 2025 evidence summary

> “In both trials, clinical remission at week 8 occurred in a significantly higher proportion of patients treated with tofacitinib 10 mg twice a day (BID) (18.5% and 16.6%, respectively) compared with those receiving placebo (8.2% and 3.6%, respectively).”
> “At 52 weeks, in the maintenance trial, 40.6% of patients treated with tofacitinib 10 mg BID and 34.3% of patients treated with 5 mg BID achieved remission compared with 11.1% of those treated with placebo.”
> “In the U-ACHIEVE induction study, 26% of patients treated with upadacitinib achieved clinical remission compared with 5% of patients receiving placebo (P < 0.0001). In the U-ACCOMPLISH trial, 34% of patients receiving upadacitinib achieved clinical remission at 8 weeks compared with 4% of patients on placebo (P < 0.0001).”
> “At the end of follow-up, clinical remission was achieved by a larger proportion of patients treated with upadacitinib 15 mg/d (42%) or 30 mg/d (52%) compared with placebo (12%; P < 0.0001 for both).”
> “Filgotinib is an additional JAK-1 selective inhibitor which has demonstrated efficacy in moderately to severely active UC and is approved for use for this indication in Europe (204). However, this therapy is not available in the United States.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.8-3"></a>

### U.S. positioning after TNF antagonist failure: ACG 2025

> “This led to a label change for tofacitinib in the United States (only in the United States) to be positioned after failure of anti-TNF.”
> “Nonetheless, tofacitinib is labeled to be used after anti-TNF failure and with caution in patients with risk factors for cardiovascular disease or VTE complications.”
> “There were no significant MACE or VTE events with upadacitinib in these trials, but the US FDA extended the label used with tofacitinib to upadacitinib to use after inadequate response or intolerance to one or more TNF inhibitors, with caution in patients with cardiovascular risk factors, and to use the lowest effective dose in maintenance.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.8-4"></a>

### Restricted first-line use: AGA 2024 guideline

> “JAK inhibitors have restricted use in advanced therapy-naïve patients. The FDA label recommends the use of JAK inhibitors in patients with prior failure or intolerance to TNF antagonists.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.1.8-5"></a>

### ECCO 2026 guideline: recommendations, safety, and European risk minimization

> “We recommend treatment with tofacitinib for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]”
> “We recommend treatment with upadacitinib for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]”
> “We recommend treatment with filgotinib for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 98%]”
> “The measures specified that JAKi should be used only if no suitable treatment alternatives are available in those aged ≥65 years and those with cardiovascular risk factors. They also recommended using JAKi with caution in patients with risk factors for venous thromboembolism.”
> “A systematic review has demonstrated that risks of herpes zoster are dose-related for both tofacitinib and upadacitinib, underscoring the importance of dose de-escalation where possible.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.8-6"></a>

### Tofacitinib: U.S. indication in ulcerative colitis

> “XELJANZ tablets and XELJANZ XR (extended-release tablets) are indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have an inadequate response or intolerance to one or more TNF blockers.”
> “Use of XELJANZ tablets or XELJANZ XR in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.”

Source: [Xeljanz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203214s042lbl.pdf)

<a id="topic-2.2.2.1.8-7"></a>

### Upadacitinib: U.S. indication and dosing in ulcerative colitis

> “RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ.”
> “The recommended induction dosage of RINVOQ is 45 mg once daily for 8 weeks.”
> “The recommended dosage of RINVOQ for maintenance treatment is 15 mg once daily. A dosage of 30 mg once daily may be considered for patients with refractory, severe or extensive disease.”

Source: [Rinvoq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218347Orig1s008,211675Orig1s034lbl.pdf)

<a id="topic-2.2.2.1.8-8"></a>

### Network meta-analyses: rankings of Janus kinase inhibitors

> “With the inclusion of JAK inhibitors as first-line therapy, upadacitinib was more efficacious compared with all other medications except ozanimod and risankizumab with low to moderate certainty evidence. In patients with prior biologic exposure, upadacitinib, tofacitinib and ustekinumab were ranked highest for achieving remission.”

Source: [Ananthakrishnan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12148344/)

> “Upadacitinib ranked highest in inducing clinical remission (99.6%), and endoscopic improvement (99.2%), followed by risankizumab (91.4%) and (82.3%), respectively.”

Source: [Shehab et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39182898/)

> “Upadacitinib demonstrated the highest relative efficacy for clinical remission (risk ratio, 6.90; 95% confidence interval, 3.54-12.45; P score, 0.95; high confidence) and endoscopic improvement (risk ratio, 5.29; 95% confidence interval, 3.38-8.28; P score, 0.97; moderate confidence).”

Source: [Olivera et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42838315/)

> “In re‐randomised studies, upadacitinib 30 mg o.d. ranked first for clinical remission (RR of failure to achieve clinical remission = 0.52; 95% CI 0.44–0.61, p‐score 0.99) and endoscopic improvement (RR = 0.43; 95% CI 0.35–0.52, p‐score 0.99).”

Source: [Barberio et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12151545/)

> “The guideline does not provide a hierarchy of treatments, due predominantly to the lack of head-to-head data, but network meta-analysis (NMA) of trials for induction and maintenance of moderate to severe UC demonstrate a large magnitude of effect for upadacitinib and tofacitinib, with moderate magnitude of effect for risankizumab, filgotinib and ozanimod, and a small magnitude of effect for infliximab, etrasimod, golimumab, mirikizumab, ustekinumab and vedolizumab.”

Source: [Butler and Segal (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7619135/)

<a id="topic-2.2.2.1.8-9"></a>

### Medicare drug price negotiation: tofacitinib selected for the third cycle

> “Any negotiated prices will be effective beginning in 2028.”
> “Xeljanz; Xeljanz XR”

Source: [CMS fact sheet, third cycle of negotiation (2026)](https://www.cms.gov/files/document/fact-sheet-medicare-drug-price-negotiation-third-cycle.pdf)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
